In a meta-analysis combining both the FHCRC and PLCO studies, four variants, HOXB13 p.Gly84Glu, TANGO2 p.Ser17Ter, OR5H14 p.Met59Val, and CHAD p.Ala342Asp, were associated with increased PCa risk (P < 0.05). Here, CHAD is linked to posterior cortical atrophy.